Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 2,250 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,250 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the transaction, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. This trade represents a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ariel Hurley also recently made the following trade(s):

• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The shares were sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Trading Up 5.9 %

Shares of Blueprint Medicines stock opened at $110.05 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90. The firm has a market cap of $6.99 billion, a PE ratio of -52.16 and a beta of 0.61. The company has a 50 day simple moving average of $94.09 and a two-hundred day simple moving average of $95.42.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same period in the previous year, the business earned ($2.20) earnings per share. The firm’s quarterly revenue was up 126.5% compared to the same quarter last year. Analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new stake in Blueprint Medicines in the second quarter worth approximately $1,060,000. Federated Hermes Inc. lifted its holdings in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after acquiring an additional 13,579 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after purchasing an additional 82,693 shares during the last quarter. Entropy Technologies LP purchased a new position in Blueprint Medicines in the 3rd quarter worth $999,000. Finally, Fred Alger Management LLC lifted its stake in Blueprint Medicines by 187.3% in the second quarter. Fred Alger Management LLC now owns 48,588 shares of the biotechnology company’s stock worth $5,237,000 after purchasing an additional 31,675 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BPMC shares. Wells Fargo & Company lowered their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Wedbush restated an “outperform” rating and set a $124.00 price target (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Monday, January 13th. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price on the stock. Finally, UBS Group assumed coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.